Trial Profile
Phase II study of pegylated liposomal doxorubicin (Caelyx) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2012
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms AROBASE
- 04 Jul 2012 Merck and Co added as associations as reported in the European Clinical Trials Database record.
- 10 Aug 2011 New trial record